Asiri Ediriwickrema

Assistant Professor

Stanford University Medical Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (14)

Intratumoral heterogeneity can affect the competitive fitness and chemoresistance of individual cancer cells. In acute myeloid leukemia (AML), both genetic and functional heterogeneity contribute to chemoresistance, resulting in relapse. Whereas the role of cell-extrinsic factors has been described for AML relapse, whether interactions between cancer cells affect chemoresistance is not fully known. In this study, we demonstrated that a dominant leukemic fraction can suppress the proliferation and expansion of other leukemic cells and that this suppression is reversible. This suppression is mediated in part by both type I and type II intra-leukemic interferon signaling and dependent on BST2. Importantly, blocking antibodies to type II interferon receptor activated the cycling of this suppressed cell fraction and sensitized the cells to subsequent chemotherapy treatment. Our findings suggest that interactions between functionally heterogeneous leukemic fractions can affect competitive fitness and treatment response, highlighting interferon signaling as a potential therapeutic target to counter chemoresistance. Significance: AML presents a significant challenge in clinical management due to its poor prognosis and high rates of relapse following chemotherapy. Using multiple models of primary human AML, we demonstrate that competitive interactions between leukemia cells affect clonal dynamics and therapy resistance, thereby identifying a potential strategy to improve patient outcomes. See related commentary by Papaioannou and Aifantis, p. 18

Year:

2026

Supplementary Figure 1 shows Suppressed leukemia cells maintain disease-initiating capacity. Supplementary Figure 2 shows iAML isogenic competition model with fluorescent G0 reporter. Supplementary Figure 3 shows Oxidative phosphorylation does not account for suppression Supplementary Figure 4 shows IFN signaling inhibits suppressed samples Supplementary Figure 5 shows BST2 contributes to IFN-mediated AML suppression. Supplementary Figure 6 shows IFN signaling is associated with chemoresistance in experimental models. Supplementary Figure 7 shows IFN signaling is associated with chemoresistance in primary AML patient samples. Supplementary Figure 8 shows Blocking IFN signaling affects cycling and chimerism of patient samples.

Year:

2026

Supplementary Table 1 shows List of genes for gene set enrichment analysis Supplementary Table 2 shows Sequences of gRNA Supplementary Table 3 shows List of antibody Supplementary Table 4 shows Sequences of primers and probes

Year:

2026

Intratumoral heterogeneity can affect the competitive fitness and chemoresistance of individual cancer cells. In acute myeloid leukemia (AML), both genetic and functional heterogeneity contribute to chemoresistance, resulting in relapse. Whereas the role of cell-extrinsic factors has been described for AML relapse, whether interactions between cancer cells affect chemoresistance is not fully known. In this study, we demonstrated that a dominant leukemic fraction can suppress the proliferation and expansion of other leukemic cells and that this suppression is reversible. This suppression is mediated in part by both type I and type II intra-leukemic interferon signaling and dependent on BST2. Importantly, blocking antibodies to type II interferon receptor activated the cycling of this suppressed cell fraction and sensitized the cells to subsequent chemotherapy treatment. Our findings suggest that interactions between functionally heterogeneous leukemic fractions can affect competitive fitness and treatment response, highlighting interferon signaling as a potential therapeutic target to counter chemoresistance. Significance: AML presents a significant challenge in clinical management due to its poor prognosis and high rates of relapse following chemotherapy. Using multiple models of primary human AML, we demonstrate that competitive interactions between leukemia cells affect clonal dynamics and therapy resistance, thereby identifying a potential strategy to improve patient outcomes. See related commentary by Papaioannou and Aifantis, p. 18

Year:

2026

Year:

2025

Introduction Technological advances and direct-to-consumer marketing have unearthed significant organic demand from patients for cancer screening and prevention. However, in the absence of strong data or guidelines, physicians have minimal support on how to approach patients in clinical practice. Methods We projected individualized probabilities of 10-year and lifetime cancer risk across a population as well as potential improvement with healthy behaviors in the UK Biobank. Results A total of 118 distinct variables were included across 38 cancer-specific models. The distribution of lifetime cancer risk had a rightward skew and wide variation for both men and women. The median lifetime cancer risk was 29.5% for men (interquartile range (IQR) 8.4%) and 21.0% for women (IQR 8.8%). If all modifiable risk factors were set to the ideal state, this decreased to 20.5% for men (IQR 3.9%) and 16.5% for women (IQR 4.9%). There was considerable overlap between age groups, with men aged 50-59 at the 90 th percentile having greater risk (11.9%) than men aged 60-70 at the 25 th percentile (11.8%), and women aged 40-49 at the 90 th percentile having greater risk (7.4%) than women aged 50-59 at the 60 th percentile (6.8%) and women aged 60-70 at the 20 th percentile (7.3%). Conclusions Lifetime cancer risk varies widely across the UK Biobank cohort, but this risk decreases substantially with healthy behaviors. There was considerable overlap in 10-year cancer risk between age groups, suggesting that future multicancer screening guidelines should account for more than age and sex as more evidence becomes available in the future.

Year:

2025

Year:

2024

Relapse of acute myeloid leukemia (AML) is highly aggressive and often treatment refractory. We analyzed previously published AML relapse cohorts and found that 40% of relapses occur without changes in driver mutations, suggesting that non-genetic mechanisms drive relapse in a large proportion of cases. We therefore characterized epigenetic patterns of AML relapse using 26 matched diagnosis-relapse samples with ATAC-seq. This analysis identified a relapse-specific chromatin accessibility signature for mutationally stable AML, suggesting that AML undergoes epigenetic evolution at relapse independent of mutational changes. Analysis of leukemia stem cell (LSC) chromatin changes at relapse indicated that this leukemic compartment underwent significantly less epigenetic evolution than non-LSCs, while epigenetic changes in non-LSCs reflected overall evolution of the bulk leukemia. Finally, we used single-cell ATAC-seq paired with mitochondrial sequencing (mtscATAC) to map clones from diagnosis into relapse along with their epigenetic features. We found that distinct mitochondrially-defined clones exhibit more similar chromatin accessibility at relapse relative to diagnosis, demonstrating convergent epigenetic evolution in relapsed AML. These results demonstrate that epigenetic evolution is a feature of relapsed AML and that convergent epigenetic evolution can occur following treatment with induction chemotherapy.

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (9)

atif saleem

Stanford University

UNITED STATES
View details

Aaron Newman

Associate Professor

Stanford University

UNITED STATES
View details

Shyam Patel

Assistant Professor

University of Massachusetts Chan Medical School

UNITED STATES
View details

Ravindra Majeti

Stanford University

UNITED STATES
View details

Daiki Karigane

Associate Professor

Tokyo Institute of Technology

JAPAN
View details

Kensuke Kayamori

Stanford University Medical Center

UNITED STATES
View details

Hiromitsu Nakauchi

Distinguished University Professor

Tokyo Medical and Dental University

JAPAN
View details

Yusuke Nakauchi

Stanford University

UNITED STATES
View details

Kyle Loh

Associate Professor and The Anthony DiGenova Endowed Faculty Scholar

Stanford University School of Medicine

UNITED STATES
View details